Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. I hope everyone on the East Coast is staying warm. Let’s get into the news today.
How low can obesity drug prices go?
Novo Nordisk has decided to cut by as much as half the U.S. list prices of its weight loss and diabetes drugs Wegovy and Ozempic — escalating an ongoing pricing war with its chief rival Eli Lilly.Continue to STAT+ to read the full story…